ORIGINAL RESEARCH article
Front. Med.
Sec. Dermatology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1559372
This article is part of the Research TopicThe pathogenesis and novel treatment options in AIBDsView all 7 articles
The serum level of interleukin-17, interleukin-18, interleukin-22 and interleukin-25 in the patients of bullous pemphigoid before and after treatment
Provisionally accepted
Xinyi Hong1,2,3,4
Xiuqin Wang1,2,3,4Yin Cheng1,2,3,4Hanqing Song2,3,4,5Congcong Xu1,2,3,4
Peiguang Wang1,2,3,4*- 1Department of Dermatology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China
- 2Institute of Dermatology, Anhui Medical University, Hefei, Anhui Province, China
- 3Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, hefei, China
- 4Collaborative Innovation Center of Complex and Severe Skin Disease, Anhui Medical University, Hefei, China
- 5Wuxi Ninth People's Hospital, Soochow University, Wuxi, Jiangsu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To explore the relationship of serum level of interleukin-17 (IL-17), interleukin-18 (IL-18), interleukin-22 (IL-22), interleukin-25 (IL-25), anti-BP180 antibodies, anti-BP230 antibodies, immunoglobulin E (IgE), and the percentage of eosinophils (EOS) in peripheral blood with the disease activity and severity in bullous pemphigoid (BP) patients.The blood samples from 61 BP inpatients were collected on the first day of admission and one week after the treatment of systemic corticosteroids respectively.Besides, the blood specimens from 61 healthy controls were also collected. The concentration of IL-17, IL-18, IL-22, IL-25, IgE, anti-BP180 antibodies, or anti-BP230 antibodies was detected by using ELISA kits. Several statistical methods were used, including the Wilcoxon test, multifactorial logistic regression, ROC survival curve, and Spearman correlation analysis.The mean serum level of IL-17, IL-18, IL-22, IL-25 , or the EOS percentage of BP patients was all higher than that of healthy controls (all p<0.001), and all were decreased after treatment (all p<0.001). There was no statistically significant difference in the titer of anti-BP180 or anti-BP230 antibodies before and after treatment. Binary multivariate logistics regression analysis indicated the statistically significant effect of IL-18, IL-25, or EOS on BP (p<0.001). Spearman correlation analysis revealed that the serum level of IL-17, IL-22, or IL-25 were all strongly correlated with the involved surface area (P<0.001). In addition, the serum level of IL-17 and the percentage of EOS were correlated with the titer of anti-BP180 antibodies (p<0.05).Conclusions: IL-17, IL-18, IL-22, IL-25, or EOS may be involved in the development of BP, and can be used as the biological indicators to monitor the disease severity.
Keywords: IL-17, IL-18, IL-22, IL-25, EOS, BP180 antibodies, BP230 antibodies, Bullous pemphigoid
Received: 12 Jan 2025; Accepted: 07 Jul 2025.
Copyright: © 2025 Hong, Wang, Cheng, Song, Xu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Peiguang Wang, Department of Dermatology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.